- Conditions
- Rheumatoid Arthritis
- Interventions
- LX3305 low dose, LX3305 mid dose, LX3305 high dose, Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Orange Park, Florida • Orlando, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2713–2736
of 7,076
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Saxagliptin, Placebo matching Saxagliptin, Metformin, Placebo matching Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 1,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 83
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 80 more
- Conditions
- Bipolar Disorder
- Interventions
- Omega-3 Supplementation, Psychoeducational Psychotherapy (PEP), Placebo
- Drug · Behavioral · Other
- Lead sponsor
- L. Eugene Arnold
- Other
- Eligibility
- 7 Years to 14 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Placebo - Control, Exogenous Ketone Salt
- Interventions
- Exogenous ketone salt, Placebo drink solution
- Dietary Supplement
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Durham, North Carolina • Canton, Ohio
- Conditions
- Carcinoid Syndrome
- Interventions
- Telotristat etiprate, Placebo-matching telotristat etiprate
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 17
- States / cities
- Mobile, Alabama • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- Depressive Disorder, Anhedonia
- Interventions
- Ezogabine, Placebos
- Drug
- Lead sponsor
- James Murrough
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC
- Interventions
- Erlotinib (tarceva), Placebo
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 57 more
- Conditions
- Schizophrenia
- Interventions
- ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C, ITI-214 Dose D (Elderly), Placebo, ITI-214 Dose E, ITI-214 Dose F, ITI-214 Dose G, ITI-214 Dose H
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Glendale, California • New York, New York
- Conditions
- Cannabis Use Disorder
- Interventions
- Clonazepam, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neoplasms
- Interventions
- Dostarlimab, Placebo matching dostarlimab, Carboplatin, Paclitaxel, Niraparib, Placebo matching Niraparib
- Biological · Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 785 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more
- Conditions
- Borderline Personality Disorder
- Interventions
- Brexpiprazole, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 66
- States / cities
- Bentonville, Arkansas • Bellflower, California • Beverly Hills, California + 56 more
- Conditions
- Acute Gout
- Interventions
- Canakinumab, Triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 27
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- REGN2477, Matching placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Cystic Fibrosis, Bronchiectasis
- Interventions
- BI 1291583, Placebo to BI 1291583
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Altamonte Springs, Florida • South Portland, Maine + 3 more
- Conditions
- Nasal Congestion
- Interventions
- Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg
- Drug
- Lead sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 1,021 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 12
- States / cities
- Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 48
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Colton, California + 39 more
- Conditions
- Alzheimer's Disease
- Interventions
- Simvastatin, Placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 40 Years to 72 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Fitchburg, Wisconsin
- Conditions
- COVID-19
- Interventions
- Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 21
- States / cities
- Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ambrisentan, Placebo, Sildenafil, Tadalafil
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Surgical Procedures
- Interventions
- GSK1278863, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
- Conditions
- Methamphetamine Dependence, Treatment Seeking
- Interventions
- Acamprosate, placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 (blinded), placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 11
- States / cities
- Bakersfield, California • San Diego, California • Miami, Florida + 8 more
- Conditions
- Velo-cardio-facial Syndrome, Psychosis
- Interventions
- Metyrosine, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Syracuse, New York